43 related articles for article (PubMed ID: 11307810)
21. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia.
Messmore H; Jeske W; Wehrmacher W; Walenga J
Drug Saf; 2003; 26(9):625-41. PubMed ID: 12814331
[TBL] [Abstract][Full Text] [Related]
22. Argatroban.
Kathiresan S; Shiomura J; Jang IK
J Thromb Thrombolysis; 2002 Feb; 13(1):41-7. PubMed ID: 11994559
[TBL] [Abstract][Full Text] [Related]
23. A synopsis of the clinical uses of argatroban.
Moledina M; Chakir M; Gandhi PJ
J Thromb Thrombolysis; 2001 Oct; 12(2):141-9. PubMed ID: 11729365
[TBL] [Abstract][Full Text] [Related]
24. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
Bartholomew JR; Hursting MJ
J Thromb Thrombolysis; 2005 Jun; 19(3):183-8. PubMed ID: 16082605
[TBL] [Abstract][Full Text] [Related]
25. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin.
Arpino PA; Demirjian Z; Van Cott EM
Pharmacotherapy; 2005 Feb; 25(2):157-64. PubMed ID: 15767231
[TBL] [Abstract][Full Text] [Related]
26. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy.
Austin JH; Stearns CR; Winkler AM; Paciullo CA
Pharmacotherapy; 2012 Jun; 32(6):493-501. PubMed ID: 22511112
[TBL] [Abstract][Full Text] [Related]
27. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
28. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
Shapiro NL; Durr EA; Krueger CD
Pharmacotherapy; 2006 Dec; 26(12):1806-10. PubMed ID: 17125442
[TBL] [Abstract][Full Text] [Related]
29. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.
Sheth SB; DiCicco RA; Hursting MJ; Montague T; Jorkasky DK
Thromb Haemost; 2001 Mar; 85(3):435-40. PubMed ID: 11307810
[TBL] [Abstract][Full Text] [Related]
30. Argatroban therapy for antithrombin deficiency and mesenteric thrombosis: case report and review of the literature.
Dager WE; Gosselin RC; Owings JT
Pharmacotherapy; 2004 May; 24(5):659-63. PubMed ID: 15162900
[TBL] [Abstract][Full Text] [Related]
31. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
[TBL] [Abstract][Full Text] [Related]
32. Surgical management of patients on warfarin sodium.
Beirne OR; Koehler JR
J Oral Maxillofac Surg; 1996 Sep; 54(9):1115-8. PubMed ID: 8811824
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
